C4 Therapeutics, INC Form 4 insider transactions

Chief Medical Officer of C4 Therapeutics, Leonard Reyno, reports a transaction involving the withholding of shares to cover tax obligations related to vested restricted stock units.

Director Donna Grogan acquired 2,836 shares of C4 Therapeutics common stock in lieu of cash compensation, while disposing of 26,468 shares on July 1, 2024.

Director Kenneth Anderson acquired 2,320 shares of C4 Therapeutics common stock in lieu of cash compensation, according to a Form 4 filing.

Director Owen Hughes acquired 32,500 stock options in C4 Therapeutics, Inc. on June 20, 2024.

Director Laura Bessen acquired stock options in C4 Therapeutics, Inc. on June 20, 2024.

Director Utpal Koppikar acquired stock options in C4 Therapeutics, Inc. on June 20, 2024.

Director Bruce Downey acquired 32,500 stock options in C4 Therapeutics, Inc. on June 20, 2024.

Director Malcolm Salter acquired stock options in C4 Therapeutics, Inc. on June 20, 2024.

Director Kenneth Carl Anderson acquired stock options in C4 Therapeutics, Inc. on June 20, 2024.

Director Donna Roy Grogan acquired 32,500 stock options in C4 Therapeutics, Inc. on June 20, 2024.

Director Ronald Harold Wilfred Cooper acquires stock options in C4 Therapeutics, Inc.

Mark Mossler, Chief Accounting Officer of C4 Therapeutics, reports the acquisition of restricted stock units and stock options.

Director Kenneth Anderson reports acquisition of shares in C4 Therapeutics through non-employee director compensation and disposition of shares, with adjustments to beneficial ownership.

Glenn Dubin, a director at C4 Therapeutics, acquired 1,358 shares of common stock in lieu of cash compensation, according to a recent SEC filing.

Director Donna Grogan acquired 1,697 shares of C4 Therapeutics common stock in lieu of cash compensation, according to a recent SEC filing.

Scott N. Boyle, Chief Business Officer of C4 Therapeutics, Inc., had stock options repriced on March 7, 2024, according to a recent SEC filing.

Stewart Fisher, Chief Scientific Officer of C4 Therapeutics, adjusts stock option holdings due to an option repricing approved by the company's Compensation Committee.

Kelly Schick, Chief People Officer at C4 Therapeutics, adjusts stock option positions following an option repricing approved by the company's Compensation Committee.

Kendra Adams, CFO of C4 Therapeutics, reports an option repricing approved by the Compensation Committee on March 7, 2024.

Jolie Siegel, Chief Legal Officer of C4 Therapeutics, reports the repricing of stock options on March 7, 2024.